Genotype-directed therapy holds great promise for the treatment of cancer, but crosstalk between signaling pathways often confounds simple genotype-drug response relationships. To deliver on the promise of precision medicine, a coordinated effort is needed to make a comprehensive inventory of the many signaling feedback circuits that exist in cancer cells.
Toward Genotype-Directed Cancer Therapy There is a trend in the treatment of cancer from an approach in which the tissue of origin and the histology were the guiding principles for the choice of therapy toward a strategy in which knowledge of the oncogenic mutations is used to select patients for treatment with highly selective drugs. This shift was enabled by two major developments over the past decades. First, the emergence of nextgeneration DNA sequencing technologies has enabled the identification of recurrent mutations in a variety of cancers. Second, the development of highly selective inhibitors of the products of genes that are activated by these frequent genomic alterations has provided medical oncologists with a new arsenal of more targeted cancer therapeutics. Obviously, such a radically new approach toward treatment also requires a different method for diagnosing cancer. In line with this, the National Academy of Sciences has published a report last year calling for a new taxonomy of disease, based on molecular rather than morphological parameters. This should ultimately enable precision medicine, in which subsets of patients can be readily identified having a disease of similar biological origin and who are therefore most likely to benefit from a specific drug treatment (Committee on a Framework for Developing a New Taxonomy of Disease, 2011) . The benefits of this new approach can be significant. Current cancer treatments are highly inefficient, delivering benefit on average to only 25% of the patients (Spear et al., 2001 ). Also, in economic terms, the conventional approach is unsustainable. Global annual spending on cancer drugs was around $49 billion in 2011, of which, by inference, some $ 37 billion was spent to cause adverse side effects without delivering patient benefit.
The Cancer Genotype as a Predictor of Response to Therapy Genotype-directed precision medicine holds the promise to greatly improve cancer survival by delivering the most effective drugs to the right patients. Indeed, great progress has been made in treatment of diseases like chronic myelogenous leukemia (CML). Current precision treatment strategies targeting the product of the BCR-ABL oncogene with targeted agents like imatinib have more than doubled 5-year survival rates of CML to >95%, a number that is similar to what is seen in the general population. This strong relationship between the BCR-ABL genotype and the response to the ABL kinase inhibitor imatinib is most readily explained by what the late Bernhard Weinstein dubbed ''oncogene addiction,'' an acquired dependence of the cancer on the ''driver'' mutation that fuels oncogenic growth (Weinstein, 2002) . This and other initial successes in targeting the oncogenic drivers of cancer have spurred globally coordinated efforts to genotype thousands of cancers. Such studies have already yielded a wealth of new information on recurrent genomic alterations in diverse cancer types. A complicating factor in using genomic information to select patients for therapy is that some cancers contain many mutations, making such tumors potentially less dependent on a single oncogenic event. Nevertheless, even today, clinicians already use the presence of a number of these genomic changes in cancer as a diagnostic tool to select patients for treatment with targeted agents. It should be pointed out, however, that in spite of the avalanche of publications on targeted cancer therapies of recent years, the vast majority of cancer patients are still treated with conventional chemotherapies, the clinical benefit of which is virtually impossible to predict for the individual patient.
Crosstalk between Signaling Pathways
Virtually all of the clinically relevant changes in cancer genomes are based on the principle that one mutation is selected for treatment with a matching drug. A complication in this simple scenario is that many of the cellular signaling pathways are interconnected to maintain homeostasis. For instance, inhibition of the mTORC1 complex with rapamycin-like drugs causes activation of phosphatidylinositol 3-kinase (PI3-kinase) and AKT, dampening a response to single-agent mTORC1 inhibitors. Similarly, inhibition of AKT leads to activation of multiple receptor tyrosine kinases (RTKs), which attenuate the effect of AKT inhibition (Chandarlapaty et al., 2011) . Moreover, inhibition of MEK in triple-negative breast cancer also causes activation of RTKs, precluding a response to singleagent MEK inhibition in vivo (Duncan et al., 2012) . These examples illustrate the dynamic interactions between the major signaling pathways in cancer. At the same time, they emphasize that targeting a single activated pathway in cancer may not yield the desired therapeutic benefit due to feedback activation of pathways that circumvent the roadblock imposed by the cancer drug.
A particularly striking example of this is the case of BRAF mutant cancers. In agreement with the oncogene addiction model, patients with BRAF(V600E) mutant melanoma respond very well to a smallmolecule inhibitor of the BRAF kinase (Chapman et al., 2011) . However, to the surprise of many, Kopetz and colleagues found that BRAF(V600E) mutant colon tumors were almost invariably resistant to the very same BRAF inhibitor that had proven to be so successful in treating melanomas with the identical BRAF mutation (S. Kopetz et al., 2010, Am. Soc. Clin. Oncol., abstract). The resolution for this apparent disparity came recently, when it was found that BRAF mutant colon cancers activate the epidermal growth factor receptor (EGFR) through a feedback mechanism upon inhibition of the BRAF kinase, which fuels proliferation in the presence of BRAF inhibition (Prahallad et al., 2012) . In contrast to colon cancer, EGFR is normally not expressed in melanoma, explaining the absence of intrinsic BRAF inhibitor resistance in melanoma. This example, in which tumor types having the very same BRAF mutation respond radically differently to BRAF inhibition, further highlights the disconnect that can exist between the genotypes of cancers and their predicted drug responses.
Functional Genetic Screens as a Tool to Map Feedback Circuits
A potential way to deal with these feedback mechanisms in the clinic is to target not only the activated oncoprotein itself, but also the pathway activated by the feedback mechanism that resulted from inhibition of the primary target. Indeed, in colon cancer cells, simultaneous inhibition of both BRAF and EGFR causes responses far beyond what can be achieved with each drug alone (Corcoran et al., 2012; Prahallad et al., 2012) . This interaction between BRAF and EGFR is referred to in genetic terms as a ''synthetic lethal'' interaction; a situation in which inhibition of each gene product alone yields no effect, but simultaneous inhibition of both is lethal to the cell. Feedback circuits are particularly likely to display synthetic lethal interactions, as the very nature of the feedback loop is often to dampen the effects of pathway inhibition ( Figure 1A) .
Unbiased discovery of synthetic lethal interactions between signaling pathways in cancer is enabled by loss-of-function genetic screens using RNA interference (A) Feedback circuits often display synthetic lethal interactions. Inhibition of a single activated component (in orange) of a major signal transduction pathway can lead to feedback activation of another signaling pathway, which supports cell viability while the oncogenic driver is inhibited (center). Only combined inhibition of both the oncogenic driver and the target of the feedback circuit leads to cell death (right). (B) Genetic screens to identify synthetic lethal interactions. Cancer cells are infected with collections of retroviral shRNA vectors. Infected cells are divided into two duplicate populations, of which one is treated with a drug that targets a cancer-specific oncogenic lesion. The cancer cell only dies when a critical component of the feedback circuit is inactivated by shRNA, leading to depletion of that specific shRNA from the population. Drug-depleted shRNA vectors can be identified through deep sequencing of bar code identifiers that are present in each shRNA vector. (Kaelin, 2005) . When inhibition of an activated oncogene alone elicits no therapeutic benefit, one can identify the redundant signaling pathway that allows cancer cell survival in the presence of drug through functional genetics. By systematic inactivation of all major nodes in signaling pathways, one can ask which other pathway needs to be inhibited to make the ineffective cancer drug effective in combination ( Figure 1B ). There are two important aspects to this particular synthetic lethality approach. First, the drug that targets the activated oncogene is, in principle, cancer selective, as only the cancer cells harbor the activated oncogene. This should, at least in theory, limit toxicity to normal tissues. Second, the gene that displays a synthetic lethal interaction with the cancer-specific mutation may not be a recurrently mutated gene in cancer itself and hence may not be a target for oncology drug discovery today. Thus, a systematic search for synthetic lethal interactions in cancer may yield a wealth of new druggable targets (kinases are often the nodes of signaling pathways) that are not active when used as single agent but become very potent when combined with their synthetic lethal drug partner. The use of synthetic lethal drug combinations may also circumvent drug resistance, an almost inevitable problem in patients with advanced cancer treated with single agents. A lesson learned from the treatment of HIV (also genetically unstable, like many human cancers) is that escape from combination therapies is much less likely. Targeting cancers with pairs of highly effective synthetic lethal drugs may therefore also reduce the emergence of drug-resistant variants and hence prolong progression free survival.
Combinations of Targeted Cancer
Therapies: Roadblocks to Implementation In spite of the logic of using combinations of targeted cancer agents, the road to clinical success of this approach is likely to be bumpy. A first issue is whether cell line models of cancer are suitable to predict which combination therapies are likely to be effective in the clinic. In the past, cell line models have not been very helpful to identify biomarkers of response to chemotherapy. However, there is reason to be more optimistic about their utility for predicting responses to (combinations of) targeted therapies. Connections between signaling pathways are often hard-wired in the cell and consequently less dependent on the microenvironment. Nevertheless, it will be important to investigate the utility of other cancer models for predicting drug responses, such as three-dimensional cell culture systems and patient-derived mouse xenograft models of cancer. A second issue that will complicate the use of combinations of targeted therapies is that these drugs too have side effects. This will limit the number of two-and three-way drug combinations that are practically feasible in the clinic while maintaining proper suppression of the intended drug targets. Finally, it is likely that functional genetic screens as outlined above will more often than not identify combinations of drugs that are being developed by different pharmaceutical or biotechnology companies. Testing such combinations will require a new model for cooperation between such companies. Fortunately, we have seen the first signs that such partnerships are indeed possible. In 2009, Merck and AstraZeneca agreed to conduct a joint phase 1 clinical trial combining AstraZeneca's MEK inhibitor with Merck's AKT inhibitor. Such partnerships are likely to become more common as we learn how we need to combine targeted therapies to maximize therapeutic responses.
A Call for a Coordinated Search for Synthetic Lethal Interactions in Cancer
The identification of synthetic lethal drug combinations as depicted in Figure 1B holds great promise for future development of effective combination therapies, but it also represents a huge logistical hurdle to accomplish. Whereas cancer genome sequencing projects are highly coordinated globally, functional genetic screens are performed by individual laboratories without any coordination. Yet, the amount of work to make a complete inventory of all crosstalk circuits between the major signaling pathways is far too large for any single laboratory to handle. As one example, BRAF and KRAS mutation are mutually exclusive in colon cancer, consistent with the notion that they both act in the RAF-RAS-MEKsignaling pathway. However, inhibition of BRAF elicits different feedback responses in BRAF mutant colon tumors than inhibition of the downstream MEK kinase in KRAS mutant colon cancer. We will therefore have to make an inventory of all signaling network interactions for all cancer genotypes in each tissue type to identify the most effective drug combinations. In spite of the significant efforts that are ongoing at individual laboratories (e.g., www.broadinstitute.org/ software/cprg/?q=node/10), a comprehensive inventory of all synthetic lethal interactions in cancer will require a globally coordinated effort, not unlike the coordination between the large genome centers that work together to sequence thousands of cancer genomes. However, coordination of functional genetic screens may represent a larger logistical hurdle in that there are no standardized reagents and no agreed standard operating procedures to perform such screens between laboratories. This lack of standardization makes it impossible at present to compare results between individual laboratories. If two laboratories perform a synthetic lethal screen and the results differ, it is impossible to know whether the differences in outcome are due to technical differences or true biological differences between the two systems. The adage ''absence of evidence is no evidence for absence,'' is most certainly applicable to RNAi screens. A gene may not show up in a genetic screen for any number of trivial technical reasons, but it can also be biologically significant that it did not show up. Only if we agree on a common set of reagents and standardized protocols to perform such screens will we be able to compare results between laboratories in a meaningful way.
Today, there is almost universal conviction that cancer genome sequencing will deliver the ingredients to select patients for individualized therapy. I argue here that, in addition, an inventory of feedback and crosstalk circuits between signaling pathways will be instrumental in finding the right drug combinations for each individual patient. Our lack of understanding of the way in which signaling networks interconnect represents a critical missing link in realizing the ultimate goal of personalized medicine. The technology to identify these connections is available, and initial proof of concept has been delivered, making the entire project feasible. What seems to be missing is a concerted funding effort and a consortium of laboratories to make this happen. It may be that this qualifies as a ''neglected area of oncology'' that the National Cancer Institute is targeting for funding through the provocative questions initiative (http://provocativequestions.nci.nih.gov). Cancer patients have much to gain from effective combination therapies based on insights into how the major signaling pathways communicate within their cancer cells.
